Trial Profile

A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms OPAL
Sponsors GlaxoSmithKline; GSK; TESARO

Most Recent Events

02 May 2025 Status changed from active, no longer recruiting to completed.
12 Aug 2024 Study phase changed from Phase 1/2 to Phase 2.
12 Aug 2024 Planned End Date changed from 31 Mar 2026 to 14 Apr 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com